Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28874064 | 0.74 | SLC6A4 (0.34) | OPRM1SLC6A4OPRD1OPRK1 | |
| SCHEMBL28302975 | 0.72 | GRIN1 (0.40) | OPRM1SLC6A4OPRD1OPRK1 | |
| SCHEMBL11662304 | 0.65 | OPRM1 (0.42) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3789360 | 0.60 | MEN1 (0.46) | OPRD1OPRK1 | |
| SCHEMBL19646503 | 0.60 | ESR1 (0.57) | OPRM1ACHEOPRD1OPRK1 | |
| SCHEMBL29769890 | 0.60 | GRIN1 (0.64) | OPRM1SLC22A1CHRM2ACHESLC6A4 | |
| SCHEMBL3080027 | 0.60 | KDM4E (0.57) | OPRM1CYP2D6OPRD1OPRK1 | |
| SCHEMBL6601752 | 0.60 | OPRD1 (0.62) | OPRM1OPRD1OPRK1 | |
| SCHEMBL20195858 | 0.60 | OPRK1 (0.40) | OPRM1CHRM2OPRD1OPRK1 | |
| SCHEMBL3411538 | 0.60 | MAOA (0.45) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810047-A | (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani | 上海博邦医药科技有限公司 | 2019-05-28 | — | — | CN | disclosed |